| 19.88 -0.62 (-3.02%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 24.95 | 1-year : | 27.14 |
| Resists | First : | 21.36 | Second : | 23.23 |
| Pivot price | 21.02 |
|||
| Supports | First : | 18.32 | Second : | 15.25 |
| MAs | MA(5) : | 20.65 |
MA(20) : | 20.62  |
| MA(100) : | 25.38 |
MA(250) : | 25.29 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 19.7 |
D(3) : | 34.5 |
| RSI | RSI(14): 40.4 |
|||
| 52-week | High : | 37.5 | Low : | 16.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LEGN ] has closed above bottom band by 10.5%. Bollinger Bands are 64.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 20.61 - 20.78 | 20.78 - 20.89 |
| Low: | 19.51 - 19.69 | 19.69 - 19.81 |
| Close: | 19.64 - 19.92 | 19.92 - 20.11 |
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Tue, 25 Aug 2026
Will Legend Biotech’s (LEGN) Move to Q2 Profitability Reshape Its Investment Narrative? - simplywall.st
Mon, 24 Aug 2026
Legend Biotech Corporation (LEGN): Investor Outlook on a Biotech Star with 125.70% Upside Potential - DirectorsTalk Interviews
Mon, 17 Aug 2026
Legend Biotech Corporation (LEGN): Investor Outlook on a Biotech Powerhouse with 141.76% Potential Upside - DirectorsTalk Interviews
Wed, 12 Aug 2026
Legend’s Pipeline Is Starting To Matter (NASDAQ:LEGN) - Seeking Alpha
Wed, 12 Aug 2026
Legend Biotech stock downgraded at Oppenheimer (LEGN:NASDAQ) - Seeking Alpha
Tue, 11 Aug 2026
Legend Biotech (NASDAQ: LEGN) surges on CARVYKTI growth and Q2 2026 profitability - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 194 (M) |
| Shares Float | 90 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 56.8 (%) |
| Shares Short | 18,110 (K) |
| Shares Short P.Month | 13,110 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.57 |
| Profit Margin | -7.2 % |
| Operating Margin | 14.8 % |
| Return on Assets (ttm) | -2 % |
| Return on Equity (ttm) | -8.1 % |
| Qtrly Rev. Growth | 51.9 % |
| Gross Profit (p.s.) | 3.69 |
| Sales Per Share | 6.52 |
| EBITDA (p.s.) | -0.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -89 (M) |
| Levered Free Cash Flow | 27 (M) |
| PE Ratio | -39.76 |
| PEG Ratio | 0 |
| Price to Book value | 3.02 |
| Price to Sales | 3.04 |
| Price to Cash Flow | -43.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|